Insider trade

Officer sold ~$1.69M of INCY shares in the open market

Traded Sep 15, 2026 · Filed Sep 17, 2026

IncyteINCY

~$1.69M
Reported value · 14K sh @ $120.49: 183K
Holds after · shares reported: -3.8%
stock since the trade · S&P 500 +0.9%, $121.74 → $117.14 on Oct 1

Why it stands out

Incyte's President, Global Head of R&D sold $1.69M of Incyte shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 15, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 17, 2026

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,685,053

Shares × reported transaction price

Timing vs results

49 days after results of Jul 28, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $121.74 on Sep 15, 2026, 49% above its 52-week low and 6% below its high, after a 3% rise over the previous 30 trading days

52-week range $81.66 (Sep 25, 2025) to $129.93 (Jul 28, 2026), 83% of the way up, from 251 adjusted closes. 30 trading days earlier: $118.43 on Aug 3, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Atebrioz on Sep 25, 2026, 10 days after this trade.

New drug application approved. Active ingredient: Zilurgisertib. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.1%	+1.3%	-2.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001205703-26-000030
Filed / recorded: Sep 17, 2026, 8:04 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: INCYTE CORP
Issuer CIK: 879169
Ticker: INCY
Reporting person: Pablo J Cagnoni
Relationship: Officer
Officer title: President, Global Head of R&D
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 15, 2026
Transaction code: S
Shares / units: 13,985
Price per share: $120.49
Acquired / disposed: Disposed (D)
Shares owned after: 183,200
Ownership form: Direct
Amendment: No

Footnotes from the filing

This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.